NeuroPace Inc — Director's Dealing 2023

Dec 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeuroPace Inc (NPCE)
CIK: 0001528287
Period of Report: 2023-12-06

Reporting Person: Morrell Martha (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-06	Common Stock	S	11005	$8.1575	Disposed	126159	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.05 to $8.265, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.